EIKN’s (NASDAQ:EIKN) Quiet Period Will End on March 17th

EIKN’s (NASDAQ:EIKN) quiet period will end on Tuesday, March 17th. EIKN had issued 21,177,600 shares in its initial public offering on February 5th. The total size of the offering was $381,196,800 based on an initial share price of $18.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

EIKN has been the subject of a number of recent research reports. Mizuho initiated coverage on shares of EIKN in a research note on Monday, March 2nd. They set an “outperform” rating and a $26.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of EIKN in a report on Monday, March 2nd. They set an “overweight” rating for the company. Zacks Research raised shares of EIKN to a “hold” rating in a research report on Friday, February 27th. Wall Street Zen cut shares of EIKN from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Morgan Stanley initiated coverage on EIKN in a report on Monday, March 2nd. They set an “overweight” rating and a $32.00 price objective for the company. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, EIKN currently has a consensus rating of “Moderate Buy” and an average target price of $25.60.

EIKN Price Performance

EIKN opened at $14.91 on Tuesday. EIKN has a fifty-two week low of $13.28 and a fifty-two week high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.